ArticlePloS one2025
Luteolin alleviates CUMS-induced depressive-like behavioral deficits in mice through blocking the JAK2/STAT3 pathway.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study probed into the potential effects of luteolin (LUT) on depressive-like behavioral deficits caused by chronic unpredictable mild stress (CUMS) in mice, with a focus on its underlying molecular mechanisms. Western blot analysis revealed that CUMS notably activated the JAK2/STAT3 pathway, as indicated by elevated levels of phosphorylated JAK2 (p-JAK2) and p-STAT3. Treatment with LUT notably diminished p-JAK2 and p-STAT3, suggesting that LUT alleviates CUMS-induced depressive-like behavioral deficits by blocking the JAK2/STAT3 pathway. Behavioral assessments, including the forced swim and sucrose preference tests, demonstrated that LUT remarkably improved depressive-like symptoms. Furthermore, LUT treatment diminished the levels of pro-inflammatory cytokines, which were elevated by CUMS, further supporting the involvement of LUT in exerting antidepressant activities via the modulation of inflammatory responses. This study is the first to integrate multidimensional evidence from behavioral tests, neuroinflammation, and the JAK2/STAT3 signaling pathway, systematically demonstrating that luteolin alleviates CUMS-induced depression-anxiety comorbidity through synergistic regulation of an antioxidant‒anti-inflammatory‒neural signaling network.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.